Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.

United States Supreme Court – 2015

“Patent claims live and die by how courts interpret words.”

SHORT DESCRIPTION

Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. is a landmark U.S. Supreme Court decision that clarified the standard of appellate review in patent claim construction disputes. The case addressed whether appellate courts should review claim interpretation entirely de novo or give deference to a trial court’s factual findings. The ruling reshaped how patent litigation is evaluated at higher judicial levels.

FACTS OF THE CASE

Teva owned a patent covering Copaxone, a widely used multiple sclerosis drug. A dispute arose over the interpretation of the term “molecular weight” within the patent claims. The ambiguity was critical because different measurement methods could yield different results, directly affecting patent validity.

The district court, after evaluating expert testimony and scientific evidence, adopted Teva’s interpretation. However, the Federal Circuit reviewed the claim construction de novo and reversed the decision, effectively invalidating the patent.

Teva challenged this approach before the Supreme Court, arguing that the Federal Circuit should have deferred to the trial court’s factual determinations.

ISSUES INVOLVED

The central issue was whether claim construction is purely a legal question subject to de novo review or whether factual determinations made by trial courts deserve judicial deference.

COURT’S FINDINGS AND OBSERVATIONS

The Supreme Court ruled in favor of Teva and established a nuanced framework. While claim construction remains primarily a legal issue, underlying factual findings made by district courts must be reviewed under the “clear error” standard, not de novo.

The Court recognized that trial judges are better positioned to evaluate expert testimony, technical evidence, and credibility assessments. Therefore, appellate courts must respect factual determinations unless clearly erroneous.

This decision reinforced judicial stability and reduced unpredictable reversals in patent disputes.

SUGGESTION / PRACTICAL TAKEAWAY

The judgment has significant implications for patent litigation strategy. Expert evidence, technical demonstrations, and factual records at the trial stage now carry greater weight. Patent drafters must minimize ambiguity, as interpretative disputes can determine patent survival.

Litigants must invest heavily in building a strong factual foundation during trial proceedings.

JUDGMENT

Year: 2015

The United States Supreme Court held that appellate courts must apply the “clear error” standard when reviewing factual findings underlying patent claim construction.